Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

Serena Di Vincenzo, Gaetano Giammona, Erika Amore, Maria Luisa Bondì, Maria Ferraro, Serena Di Vincenzo, Mark Gjomarkaj, Erika Amore, Valeria La Parola, Elisabetta Pace, Donatella Valenti, Maria Letizia Manca, Maria Elisabetta Pace, Maria Luisa Bondi', Valeria La Parola

Risultato della ricerca: Article

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.
Lingua originaleEnglish
pagine (da-a)351-358
Numero di pagine8
RivistaInternational Journal of Pharmaceutics
Volume562
Stato di pubblicazionePublished - 2019

Fingerprint

Chronic Obstructive Pulmonary Disease
Therapeutic Uses
Lipids
Epithelial Cells
Drug Evaluation
Inhalation
Pneumonia
Therapeutics
Epithelium
Lung
Salmeterol Xinafoate
Global Health

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cita questo

Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment. / Di Vincenzo, Serena; Giammona, Gaetano; Amore, Erika; Bondì, Maria Luisa; Ferraro, Maria; Di Vincenzo, Serena; Gjomarkaj, Mark; Amore, Erika; La Parola, Valeria; Pace, Elisabetta; Valenti, Donatella; Manca, Maria Letizia; Pace, Maria Elisabetta; Bondi', Maria Luisa; La Parola, Valeria.

In: International Journal of Pharmaceutics, Vol. 562, 2019, pag. 351-358.

Risultato della ricerca: Article

Di Vincenzo, S, Giammona, G, Amore, E, Bondì, ML, Ferraro, M, Di Vincenzo, S, Gjomarkaj, M, Amore, E, La Parola, V, Pace, E, Valenti, D, Manca, ML, Pace, ME, Bondi', ML & La Parola, V 2019, 'Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment', International Journal of Pharmaceutics, vol. 562, pagg. 351-358.
Di Vincenzo, Serena ; Giammona, Gaetano ; Amore, Erika ; Bondì, Maria Luisa ; Ferraro, Maria ; Di Vincenzo, Serena ; Gjomarkaj, Mark ; Amore, Erika ; La Parola, Valeria ; Pace, Elisabetta ; Valenti, Donatella ; Manca, Maria Letizia ; Pace, Maria Elisabetta ; Bondi', Maria Luisa ; La Parola, Valeria. / Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment. In: International Journal of Pharmaceutics. 2019 ; Vol. 562. pagg. 351-358.
@article{5137d06e1f1547b5b58701500fd0efb3,
title = "Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment",
abstract = "Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.",
keywords = "3003, Aerodynamic diameter, Chronic obstructive pulmonary disease (COPD), Salmeterol Xinafoate (SX), Sodium alginate polymer, cAMP",
author = "{Di Vincenzo}, Serena and Gaetano Giammona and Erika Amore and Bond{\`i}, {Maria Luisa} and Maria Ferraro and {Di Vincenzo}, Serena and Mark Gjomarkaj and Erika Amore and {La Parola}, Valeria and Elisabetta Pace and Donatella Valenti and Manca, {Maria Letizia} and Pace, {Maria Elisabetta} and Bondi', {Maria Luisa} and {La Parola}, Valeria",
year = "2019",
language = "English",
volume = "562",
pages = "351--358",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

AU - Di Vincenzo, Serena

AU - Giammona, Gaetano

AU - Amore, Erika

AU - Bondì, Maria Luisa

AU - Ferraro, Maria

AU - Di Vincenzo, Serena

AU - Gjomarkaj, Mark

AU - Amore, Erika

AU - La Parola, Valeria

AU - Pace, Elisabetta

AU - Valenti, Donatella

AU - Manca, Maria Letizia

AU - Pace, Maria Elisabetta

AU - Bondi', Maria Luisa

AU - La Parola, Valeria

PY - 2019

Y1 - 2019

N2 - Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.

AB - Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.

KW - 3003

KW - Aerodynamic diameter

KW - Chronic obstructive pulmonary disease (COPD)

KW - Salmeterol Xinafoate (SX)

KW - Sodium alginate polymer

KW - cAMP

UR - http://hdl.handle.net/10447/354002

UR - http://www.elsevier.com/locate/ijpharm

M3 - Article

VL - 562

SP - 351

EP - 358

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -